Fate Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Fate Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| collaboration revenue | 1,907,000 | 1,629,000 | 1,860,000 | 3,074,000 | 6,772,000 | 1,925,000 | 1,676,000 | 1,944,000 | 933,000 | 58,980,000 | 44,356,000 | 14,981,000 | 18,549,000 | 18,414,000 | 17,069,000 | 14,225,000 | 13,412,000 | 11,142,000 | 15,896,000 | 7,558,000 | 5,465,000 | 2,515,000 | 2,802,000 | 2,429,000 | 2,817,000 | 2,632,000 | 1,661,000 | 1,026,000 | 1,027,000 | 1,026,000 | 1,027,000 | 1,026,000 | 1,026,000 | 1,027,000 | 1,027,000 | 1,026,000 | 1,027,000 | 1,322,000 | 1,076,000 | 1,026,000 | 329,000 | 209,000 | ||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||||||||||||
| research and development | 27,430,000 | 29,136,000 | 33,609,000 | 34,650,000 | 34,604,000 | 32,138,000 | 31,816,000 | 34,275,000 | 40,876,000 | 65,629,000 | 87,191,000 | 79,817,000 | 81,307,000 | 72,139,000 | 69,515,000 | 53,130,000 | 48,023,000 | 44,852,000 | 38,982,000 | 30,694,000 | 26,669,000 | 29,278,000 | 25,209,000 | 23,202,000 | 21,631,000 | 17,728,000 | 14,095,000 | 13,637,000 | 16,816,000 | 11,476,000 | 9,887,000 | 8,578,000 | 7,927,000 | 7,966,000 | 6,230,000 | 6,804,000 | 6,782,000 | 6,636,000 | 5,433,000 | 5,003,000 | 4,857,000 | 4,568,000 | 4,080,000 | 3,968,000 | 4,522,000 | 3,378,000 |
| general and administrative | 11,445,000 | 13,773,000 | 15,262,000 | 20,801,000 | 17,251,000 | 20,855,000 | 17,935,000 | 18,948,000 | 22,622,000 | 21,943,000 | 21,584,000 | 21,555,000 | 20,351,000 | 20,742,000 | 16,936,000 | 15,718,000 | 12,168,000 | 12,500,000 | 10,313,000 | 8,351,000 | 7,503,000 | 7,729,000 | 6,671,000 | 6,346,000 | 5,270,000 | 5,350,000 | 4,307,000 | 4,081,000 | 3,816,000 | 3,604,000 | 3,384,000 | 2,788,000 | 2,669,000 | 3,032,000 | 2,451,000 | 2,611,000 | 2,249,000 | 2,602,000 | 2,555,000 | 2,351,000 | 2,690,000 | 2,756,000 | 1,904,000 | 2,072,000 | 2,415,000 | 1,979,000 |
| total operating expenses | 38,875,000 | 42,909,000 | 63,608,000 | 55,451,000 | 51,855,000 | 52,993,000 | 49,751,000 | 53,223,000 | 63,498,000 | 87,572,000 | 108,775,000 | 101,372,000 | 101,658,000 | 92,881,000 | 86,451,000 | 68,848,000 | 60,191,000 | 57,352,000 | 49,295,000 | 39,045,000 | 34,172,000 | 37,007,000 | 31,880,000 | 29,548,000 | 26,901,000 | 23,078,000 | 18,402,000 | 17,718,000 | 20,632,000 | 15,080,000 | 13,271,000 | 11,366,000 | 10,596,000 | 10,998,000 | 8,681,000 | 9,415,000 | 9,031,000 | 9,238,000 | 7,988,000 | 7,354,000 | 7,547,000 | 7,324,000 | 5,984,000 | 6,040,000 | 6,937,000 | 5,357,000 |
| income from operations | -36,968,000 | -41,280,000 | -61,748,000 | -52,377,000 | -45,083,000 | -51,068,000 | -48,075,000 | -51,279,000 | -62,565,000 | -28,592,000 | -64,419,000 | -86,391,000 | -83,109,000 | -74,467,000 | -69,382,000 | -54,623,000 | -46,779,000 | -46,210,000 | -33,399,000 | -31,487,000 | -28,707,000 | -34,492,000 | -29,078,000 | -27,119,000 | -24,084,000 | -20,446,000 | -16,741,000 | -16,692,000 | -19,605,000 | -14,054,000 | -12,244,000 | -10,340,000 | -9,570,000 | -9,971,000 | -7,654,000 | -8,389,000 | -8,004,000 | -7,916,000 | ||||||||
| yoy | -18.00% | -19.17% | 28.44% | 2.14% | -27.94% | 78.61% | -25.37% | -40.64% | -24.72% | -61.60% | -7.15% | 58.16% | 77.66% | 61.15% | 107.74% | 73.48% | 62.95% | 33.97% | 14.86% | 16.11% | 19.20% | 68.70% | 73.69% | 62.47% | 22.85% | 45.48% | 36.73% | 61.43% | 104.86% | 40.95% | 59.97% | 23.26% | 19.57% | 25.96% | ||||||||||||
| qoq | -10.45% | -33.15% | 17.89% | 16.18% | -11.72% | 6.23% | -6.25% | -18.04% | 118.82% | -55.62% | -25.43% | 3.95% | 11.61% | 7.33% | 27.02% | 16.77% | 1.23% | 38.36% | 6.07% | 9.68% | -16.77% | 18.62% | 7.22% | 12.60% | 17.79% | 22.13% | 0.29% | -14.86% | 39.50% | 14.78% | 18.41% | 8.05% | -4.02% | 30.27% | -8.76% | 4.81% | 1.11% | |||||||||
| operating margin % | ||||||||||||||||||||||||||||||||||||||||||||||
| other income: | ||||||||||||||||||||||||||||||||||||||||||||||
| interest income | 2,921,000 | 3,336,000 | 3,874,000 | 4,438,000 | 4,827,000 | 4,149,000 | 4,414,000 | 4,697,000 | 4,381,000 | 3,694,000 | 2,880,000 | 1,787,000 | 757,000 | 418,000 | 297,000 | 289,000 | 346,000 | 377,000 | 346,000 | 447,000 | 635,000 | 972,000 | 1,314,000 | 910,000 | 1,015,000 | 1,091,000 | 1,144,000 | 339,000 | 376,000 | 331,000 | 159,000 | 152,000 | 137,000 | 111,000 | 43,000 | 37,000 | 31,000 | 27,000 | 3,000 | 4,000 | 2,000 | 1,000 | 1,000 | |||
| change in fair value of stock price appreciation milestones | -73,000 | 280,000 | 670,000 | -13,000 | 1,556,000 | -1,394,000 | -645,000 | 1,049,000 | 393,000 | 1,718,000 | 5,176,000 | 891,000 | 5,881,000 | 8,359,000 | 464,000 | 11,026,000 | -8,700,000 | 744,000 | -20,058,000 | -27,644,000 | ||||||||||||||||||||||||||
| other income | 50,000 | 43,000 | 5,051,000 | 274,000 | 273,000 | 309,000 | 184,000 | 363,000 | 5,036,000 | 4,299,000 | 150,000 | 366,000 | ||||||||||||||||||||||||||||||||||
| total other income | 2,898,000 | 3,659,000 | 9,595,000 | 4,699,000 | 6,656,000 | 3,064,000 | 3,953,000 | 6,109,000 | 9,810,000 | 9,711,000 | 8,056,000 | 2,828,000 | 7,004,000 | 8,777,000 | 761,000 | 11,315,000 | -8,354,000 | 1,121,000 | -19,712,000 | -27,197,000 | 635,000 | 972,000 | 776,000 | 510,000 | 606,000 | 686,000 | 714,000 | -90,000 | -49,000 | -81,000 | -253,000 | -344,000 | -75,000 | -155,000 | -286,000 | -348,000 | -404,000 | -461,000 | ||||||||
| net income | -34,070,000 | -37,621,000 | -52,153,000 | -47,678,000 | -38,427,000 | -48,004,000 | -44,122,000 | -45,170,000 | -52,755,000 | -18,881,000 | -56,363,000 | -83,563,000 | -76,105,000 | -65,690,000 | -68,621,000 | -43,308,000 | -55,133,000 | -45,089,000 | -53,111,000 | -58,684,000 | -28,072,000 | -33,520,000 | -28,302,000 | -26,609,000 | -23,478,000 | -19,760,000 | -16,027,000 | -16,782,000 | -19,654,000 | -14,135,000 | -12,497,000 | -10,684,000 | -9,645,000 | -10,126,000 | -7,940,000 | -8,737,000 | -8,408,000 | -8,377,000 | ||||||||
| yoy | -11.34% | -21.63% | 18.20% | 5.55% | -27.16% | 154.25% | -21.72% | -45.94% | -30.68% | -71.26% | -17.86% | 92.95% | 38.04% | 45.69% | 29.20% | -26.20% | 96.40% | 34.51% | 87.66% | 120.54% | 19.57% | 69.64% | 76.59% | 58.56% | 19.46% | 39.79% | 28.25% | 57.08% | 103.77% | 39.59% | 57.39% | 22.28% | 14.71% | 20.88% | ||||||||||||
| qoq | -9.44% | -27.86% | 9.39% | 24.07% | -19.95% | 8.80% | -2.32% | -14.38% | 179.41% | -66.50% | -32.55% | 9.80% | 15.85% | -4.27% | 58.45% | -21.45% | 22.28% | -15.10% | -9.50% | 109.05% | -16.25% | 18.44% | 6.36% | 13.34% | 18.82% | 23.29% | -4.50% | -14.61% | 39.04% | 13.11% | 16.97% | 10.77% | -4.75% | 27.53% | -9.12% | 3.91% | 0.37% | |||||||||
| net income margin % | 0% | |||||||||||||||||||||||||||||||||||||||||||||
| other comprehensive loss: | ||||||||||||||||||||||||||||||||||||||||||||||
| unrealized loss on available-for-sale securities | -129,000 | -77,000 | -2,088,000 | -2,000 | -10,000 | |||||||||||||||||||||||||||||||||||||||||
| comprehensive loss | -34,199,000 | -37,698,000 | -52,720,000 | -46,421,000 | -38,655,000 | -48,213,000 | -43,608,000 | -45,082,000 | -52,696,000 | -17,673,000 | -54,964,000 | -83,435,000 | -76,636,000 | -67,778,000 | -69,310,000 | -43,295,000 | -54,959,000 | -45,419,000 | -53,353,000 | -58,995,000 | -27,591,000 | -33,400,000 | -28,331,000 | -26,651,000 | -23,385,000 | -19,758,000 | -16,015,000 | -16,781,000 | -19,656,000 | -14,145,000 | -12,487,000 | -10,658,000 | -9,650,000 | -10,159,000 | -7,944,000 | -8,745,000 | -8,411,000 | -8,363,000 | ||||||||
| net income per common share, basic and diluted | -290 | -320 | -450 | -400 | -330 | -470 | -450 | -460 | -540 | -190 | -580 | -860 | -790 | -680 | -720 | -450 | -580 | -480 | -610 | -680 | -350 | -440 | -380 | -400 | -360 | -300 | -240 | -310 | -370 | -270 | -280 | -260 | -230 | -240 | -200 | -270 | -290 | -290 | -260 | -240 | -330 | -380 | -320 | -300 | -340 | -4,810 |
| weighted-average common shares used to compute basic and diluted net income per share | 118,528,046 | 118,375,540 | 117,769,161 | 117,468,124 | 101,104,345 | 98,568,012 | 98,400,355 | 98,054,687 | 97,023,506 | 96,704,413 | 96,343,529 | 95,409,201 | 94,326,648 | 93,431,877 | 86,887,280 | 79,304,627 | 75,886,964 | 66,929,503 | 65,213,364 | 64,920,621 | 54,185,022 | 53,130,518 | 52,763,306 | 41,428,845 | 41,406,367 | 41,388,329 | 32,090,174 | 28,868,464 | 28,777,790 | 28,650,356 | 23,920,630 | 20,554,478 | 20,489,181 | 20,467,782 | 20,346,856 | |||||||||||
| other comprehensive income: | ||||||||||||||||||||||||||||||||||||||||||||||
| unrealized gain on available-for-sale securities | -567,000 | 1,257,000 | -228,000 | -209,000 | 514,000 | 88,000 | 59,000 | 1,208,000 | 1,399,000 | 128,000 | -531,000 | -689,000 | 13,000 | 174,000 | -330,000 | -242,000 | -311,000 | 481,000 | 120,000 | -29,000 | -42,000 | 93,000 | 2,000 | 12,000 | 1,000 | -3,000 | 26,000 | -5,000 | -33,000 | 750 | -8,000 | -3,000 | 14,000 | |||||||||||||
| interest expense | -538,000 | -400,000 | -409,000 | -405,000 | -430,000 | -429,000 | -425,000 | -412,000 | -412,000 | -378,000 | -212,000 | -266,000 | -329,000 | -385,000 | -435,000 | -488,000 | ||||||||||||||||||||||||||||||
| loss on extinguishment of debt | -118,000 | |||||||||||||||||||||||||||||||||||||||||||||
| net income and comprehensive loss | -7,446,000 | -6,886,000 | -7,779,000 | -7,881,000 | -6,603,000 | -6,067,000 | -6,980,000 | -6,073,000 | ||||||||||||||||||||||||||||||||||||||
| revenues: | ||||||||||||||||||||||||||||||||||||||||||||||
| grant revenue | ||||||||||||||||||||||||||||||||||||||||||||||
| total revenue | 209,000 | |||||||||||||||||||||||||||||||||||||||||||||
| yoy | ||||||||||||||||||||||||||||||||||||||||||||||
| qoq | ||||||||||||||||||||||||||||||||||||||||||||||
| change in fair value of exchangeable shares | ||||||||||||||||||||||||||||||||||||||||||||||
| change in fair value of warrant liability | ||||||||||||||||||||||||||||||||||||||||||||||
| income from 48d tax credit | ||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average shares used for eps calculation | 1,262,546,000 |
We provide you with 20 years income statements for Fate Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Fate Therapeutics stock. Explore the full financial landscape of Fate Therapeutics stock with our expertly curated income statements.
The information provided in this report about Fate Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.